A Brief View of Molecular Modeling Approaches to P2 Receptors

Purinergic receptors are a class of receptors distributed into two groups, P1 and P2. P1 receptors are activated by nucleosides, like adenosine, while nucleotides active P2 receptors. In turn, P2 receptors comprise two families, metabotropic P2Y and ionotropic P2X. P2Y receptors consist in eight members, namely, P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, and P2Y14, described in mammals, while P2X includes seven members, numbered P2X1 to P2X7. These receptors have been described as expressed in practically all cells studied to date. In this context, P2 receptors are suggested as participating in certain diseases. The general approach applied in the discovery of new drugs is expensive and lengthy. Alternatively, in the last 20 years, molecular modeling has emerged as an exciting tool for the design of new drugs, in less time and at low costs. These tools allow for in silico testing of thousands of molecules against a target protein, as well as toxicity, absorption, distribution, metabolism, and constant affinity predictions of a given interaction. Thus, molecular modeling algorithms emerge as an increasingly important tool for the design of drugs targeting purinergic receptors as therapeutic targets of many diseases, including cancer, pain, inflammation, cardiovascular, and endocrine conditions.

[1]  S. Adelman Quantum generalized Langevin equation approach to gas/solid collisions , 1976 .

[2]  R. North,et al.  A new class of ligand-gated ion channel defined by P2X receptor for extracellular ATP , 1994, Nature.

[3]  D. Julius,et al.  New structural motif for ligand-gated ion channels defined by an ionotropic ATP receptor , 1994, Nature.

[4]  M. James,et al.  A critical assessment of comparative molecular modeling of tertiary structures of proteins * , 1995, Proteins.

[5]  R. North,et al.  Pharmacological characterization of heterologously expressed ATP-gated cation channels (P2x purinoceptors). , 1995, Molecular pharmacology.

[6]  J. T. Turner,et al.  Site-directed Mutagenesis of P2U Purinoceptors , 1995, The Journal of Biological Chemistry.

[7]  K. Jacobson,et al.  Modelling the P2Y purinoceptor using rhodopsin as template. , 1995, Drug design and discovery.

[8]  G. Burnstock,et al.  A P2X purinoceptor expressed by a subset of sensory neurons , 1995, Nature.

[9]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[10]  R. Coutinho-Silva,et al.  P2Z purinoceptor-associated pores induced by extracellular ATP in macrophages and J774 cells. , 1997, American journal of physiology. Cell physiology.

[11]  S. Moro,et al.  Human P2Y1 receptor: molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites. , 1998, Journal of medicinal chemistry.

[12]  Richard Bonneau,et al.  Ab initio protein structure prediction of CASP III targets using ROSETTA , 1999, Proteins.

[13]  S. Moro,et al.  Synthesis, biological activity, and molecular modeling of ribose-modified deoxyadenosine bisphosphate analogues as P2Y(1) receptor ligands. , 2000, Journal of medicinal chemistry.

[14]  K. Jacobson,et al.  Acyclic and cyclopropyl analogues of adenosine bisphosphate antagonists of the P2Y1 receptor: structure-activity relationships and receptor docking. , 2001, Journal of medicinal chemistry.

[15]  H. Jaap van den Herik,et al.  Games solved: Now and in the future , 2002, Artif. Intell..

[16]  P. Whittaker What is the relevance of bioinformatics to pharmacology? , 2003, Trends in pharmacological sciences.

[17]  Christian F. Schwenk,et al.  Classical and QM/MM molecular dynamics simulations of Co2+ in water , 2003 .

[18]  K. Jacobson,et al.  Architecture of P2Y nucleotide receptors: structural comparison based on sequence analysis, mutagenesis, and homology modeling. , 2004, Journal of medicinal chemistry.

[19]  Corinna Cortes,et al.  Support-Vector Networks , 1995, Machine Learning.

[20]  D. Major,et al.  Molecular recognition in purinergic receptors. 2. Diastereoselectivity of the h-P2Y1-receptor. , 2004, Journal of medicinal chemistry.

[21]  Hege S. Beard,et al.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.

[22]  D. Major,et al.  Molecular recognition in purinergic receptors. 1. A comprehensive computational study of the h-P2Y1-receptor. , 2004, Journal of medicinal chemistry.

[23]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[24]  Sean Ekins,et al.  Reengineering the pharmaceutical industry by crash-testing molecules. , 2005, Drug discovery today.

[25]  K. Jacobson,et al.  Human P2Y(6) receptor: molecular modeling leads to the rational design of a novel agonist based on a unique conformational preference. , 2005, Journal of medicinal chemistry.

[26]  Weiliang Zhu,et al.  New technologies in computer-aided drug design: Toward target identification and new chemical entity discovery , 2006, Drug Discovery Today: Technologies.

[27]  K. Jacobson,et al.  Structure activity and molecular modeling analyses of ribose- and base-modified uridine 5'-triphosphate analogues at the human P2Y2 and P2Y4 receptors. , 2006, Biochemical pharmacology.

[28]  B. Honig,et al.  On the accuracy of homology modeling and sequence alignment methods applied to membrane proteins. , 2006, Biophysical journal.

[29]  R. Copeland,et al.  Drug–target residence time and its implications for lead optimization , 2007, Nature Reviews Drug Discovery.

[30]  Zonghe Yan,et al.  Participation of the Lys313-Ile333 Sequence of the Purinergic P2X4 Receptor in Agonist Binding and Transduction of Signals to the Channel Gate* , 2006, Journal of Biological Chemistry.

[31]  G. Reiser,et al.  Structure and ligand-binding site characteristics of the human P2Y11 nucleotide receptor deduced from computational modelling and mutational analysis. , 2007, The Biochemical journal.

[32]  Ben M. Webb,et al.  Comparative Protein Structure Modeling Using MODELLER , 2007, Current protocols in protein science.

[33]  S. Ekins,et al.  In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling , 2007, British journal of pharmacology.

[34]  K. Jacobson,et al.  P2Y1 antagonists: combining receptor-based modeling and QSAR for a quantitative prediction of the biological activity based on consensus scoring. , 2007, Journal of medicinal chemistry.

[35]  G. Morris,et al.  Molecular docking. , 2008, Methods in molecular biology.

[36]  Ross C. Walker,et al.  The implementation of a fast and accurate QM/MM potential method in Amber , 2008, J. Comput. Chem..

[37]  P. Biggin,et al.  Molecular dynamics simulations of membrane proteins. , 2008, Methods in molecular biology.

[38]  D. Spray,et al.  P2X7 receptor-Pannexin1 complex: pharmacology and signaling. , 2008, American journal of physiology. Cell physiology.

[39]  B. Testa,et al.  The Biochemistry of Drug Metabolism – An Introduction , 2009, Chemistry & biodiversity.

[40]  C. Müller,et al.  Key determinants of nucleotide-activated G protein-coupled P2Y(2) receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling. , 2009, Journal of medicinal chemistry.

[41]  E. Gouaux,et al.  Crystal structure of the ATP-gated P2X4 ion channel in the closed state , 2009, Nature.

[42]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[43]  R. Evans Structural interpretation of P2X receptor mutagenesis studies on drug action , 2010, British journal of pharmacology.

[44]  G. Schmalzing,et al.  Amino acid residues constituting the agonist binding site of the human P2X3 receptor and subunit stoichiometry of heteromeric P2X2/3 and P2X2/6 receptors , 2012 .

[45]  R. North,et al.  New structure enlivens interest in P2X receptors , 2010, Trends in pharmacological sciences.

[46]  Francesca Deflorian,et al.  Comparison of three GPCR structural templates for modeling of the P2Y12 nucleotide receptor , 2011, J. Comput. Aided Mol. Des..

[47]  S. Silberberg,et al.  Ion access pathway to the transmembrane pore in P2X receptor channels , 2011, The Journal of general physiology.

[48]  Weiliang Zhu,et al.  Utilization of halogen bond in lead optimization: a case study of rational design of potent phosphodiesterase type 5 (PDE5) inhibitors. , 2011, Journal of medicinal chemistry.

[49]  B. Khakh,et al.  Preferential use of unobstructed lateral portals as the access route to the pore of human ATP-gated ion channels (P2X receptors) , 2011, Proceedings of the National Academy of Sciences.

[50]  Jacobson,et al.  Pyrimidine nucleotides with 4-alkyloxyimino and terminal tetraphosphate δ-ester modifications as selective agonists of the P2Y(4) receptor. , 2011, Journal of medicinal chemistry.

[51]  J. Mccammon,et al.  Molecular recognition in the case of flexible targets. , 2011, Current pharmaceutical design.

[52]  S. Robinson,et al.  CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs , 2012, Clinical Cancer Research.

[53]  Pranita P. Kore,et al.  Computer-Aided Drug Design: An Innovative Tool for Modeling , 2012 .

[54]  Huan‐Xiang Zhou,et al.  Gating mechanism of a P2X4 receptor developed from normal mode analysis and molecular dynamics simulations , 2012, Proceedings of the National Academy of Sciences.

[55]  R. Schmid,et al.  Agonist binding evokes extensive conformational changes in the extracellular domain of the ATP-gated human P2X1 receptor ion channel , 2012, Proceedings of the National Academy of Sciences.

[56]  A. Taly,et al.  Tightening of the ATP‐binding sites induces the opening of P2X receptor channels , 2012, The EMBO journal.

[57]  K. Jacobson,et al.  Virtual screening leads to the discovery of novel non-nucleotide P2Y₁ receptor antagonists. , 2012, Bioorganic & medicinal chemistry.

[58]  M. Hattori,et al.  Molecular mechanism of ATP binding and ion channel activation in P2X receptors , 2012, Nature.

[59]  K. Jacobson,et al.  Molecular Structure of P2Y Receptors: Mutagenesis, Modeling, and Chemical Probes. , 2012, Wiley interdisciplinary reviews. Membrane transport and signaling.

[60]  G. Bahrenberg,et al.  Salt Bridge Switching from Arg290/Glu167 to Arg290/ATP Promotes the Closed-to-Open Transition of the P2X2 Receptor , 2013, Molecular Pharmacology.

[61]  S. Silberberg,et al.  Inter- and intrasubunit interactions between transmembrane helices in the open state of P2X receptor channels , 2013, Proceedings of the National Academy of Sciences.

[62]  R. North,et al.  P2X7 Receptor Channels Allow Direct Permeation of Nanometer-Sized Dyes , 2013, The Journal of Neuroscience.

[63]  L. A. Alves,et al.  Is pannexin the pore associated with the P2X7 receptor? , 2013, Naunyn-Schmiedeberg's Archives of Pharmacology.

[64]  G. Vistoli,et al.  Naturally occurring N(6)-substituted adenosines (cytokinin ribosides) are in vitro inhibitors of platelet aggregation: an in silico evaluation of their interaction with the P2Y(12) receptor. , 2014, Bioorganic & medicinal chemistry letters.

[65]  Kyle A. Brown,et al.  Exploring a 2-Naphthoic Acid Template for the Structure-Based Design of P2Y14 Receptor Antagonist Molecular Probes , 2014, ACS chemical biology.

[66]  Yang Yang,et al.  Relative motions between left flipper and dorsal fin domains favour P2X4 receptor activation , 2014, Nature Communications.

[67]  Hualiang Jiang,et al.  Agonist-bound structure of the human P2Y12 receptor , 2014, Nature.

[68]  R. North,et al.  Ectodomain Movements of an ATP-gated Ion Channel (P2X2 Receptor) Probed by Disulfide Locking* , 2014, The Journal of Biological Chemistry.

[69]  Steven M. Moss,et al.  Structure of the human P2Y12 receptor in complex with an antithrombotic drug , 2014, Nature.

[70]  Qiang Zhao,et al.  Modeling ligand recognition at the P2Y12 receptor in light of X-ray structural information , 2015, Journal of Computer-Aided Molecular Design.

[71]  Hualiang Jiang,et al.  Two disparate ligand-binding sites in the human P2Y1 receptor , 2015, Nature.

[72]  Kyle A. Brown,et al.  Design, synthesis, pharmacological characterization of a fluorescent agonist of the P2Y₁₄ receptor. , 2015, Bioorganic & medicinal chemistry letters.

[73]  K. Jacobson,et al.  Molecular modeling of the human P2Y14 receptor: A template for structure-based design of selective agonist ligands. , 2015, Bioorganic & medicinal chemistry.

[74]  Yu-chian Chen Beware of docking! , 2015, Trends in pharmacological sciences.

[75]  G. Bifulco,et al.  Molecular mechanism of tanshinone IIA and cryptotanshinone in platelet anti-aggregating effects: an integrated study of pharmacology and computational analysis. , 2015, Fitoterapia.

[76]  William J. Allen,et al.  DOCK 6: Impact of new features and current docking performance , 2015, J. Comput. Chem..

[77]  Antonio Lavecchia,et al.  Machine-learning approaches in drug discovery: methods and applications. , 2015, Drug discovery today.

[78]  N. Heinrich,et al.  Computational Chemistry in the Pharmaceutical Industry: From Childhood to Adolescence , 2015, ChemMedChem.

[79]  Daniel B. Roche,et al.  Proteins and Their Interacting Partners: An Introduction to Protein–Ligand Binding Site Prediction Methods , 2015, International journal of molecular sciences.

[80]  G. Marucci,et al.  Purinergic P2X receptors: structural models and analysis of ligand-target interaction. , 2015, European journal of medicinal chemistry.

[81]  Rafael C. Bernardi,et al.  Enhanced sampling techniques in molecular dynamics simulations of biological systems. , 2015, Biochimica et biophysica acta.

[82]  U. Rothlisberger,et al.  Mixed Quantum Mechanical/Molecular Mechanical Molecular Dynamics Simulations of Biological Systems in Ground and Electronically Excited States. , 2015, Chemical reviews.

[83]  M. Young,et al.  Purinergic P2X receptors: structural and functional features depicted by X-ray and molecular modelling studies. , 2014, Current medicinal chemistry.

[84]  Claudio N. Cavasotto,et al.  Open challenges in structure-based virtual screening: Receptor modeling, target flexibility consideration and active site water molecules description. , 2015, Archives of biochemistry and biophysics.

[85]  Jeffrey J. Gray,et al.  Computational modeling of membrane proteins , 2015, Proteins.

[86]  Kyle A. Brown,et al.  Structure-Based Design of 3-(4-Aryl-1H-1,2,3-triazol-1-yl)-Biphenyl Derivatives as P2Y14 Receptor Antagonists , 2016, Journal of medicinal chemistry.

[87]  Ben M. Webb,et al.  Comparative Protein Structure Modeling Using MODELLER , 2016, Current protocols in bioinformatics.

[88]  E. Gouaux,et al.  X-ray structures define human P2X3 receptor gating cycle and antagonist action , 2016, Nature.

[89]  Christopher A. Voigt,et al.  Synthetic biology to access and expand nature's chemical diversity , 2016, Nature Reviews Microbiology.

[90]  T. Kawate,et al.  Structural basis for subtype-specific inhibition of the P2X7 receptor , 2016, eLife.

[91]  C. Fishwick,et al.  Structure-based identification and characterisation of structurally novel human P2X7 receptor antagonists , 2016, Biochemical pharmacology.

[92]  F. Metzger,et al.  Specific Correction of Alternative Survival Motor Neuron 2 Splicing by Small Molecules: Discovery of a Potential Novel Medicine To Treat Spinal Muscular Atrophy. , 2016, Journal of medicinal chemistry.

[93]  T. Grutter,et al.  Molecular structure and function of P2X receptors , 2016, Neuropharmacology.

[94]  Alexander S. Bayden,et al.  The Roles of Water in the Protein Matrix: A Largely Untapped Resource for Drug Discovery. , 2017, Journal of medicinal chemistry.

[95]  O. Nureki,et al.  Structural insights into the competitive inhibition of the ATP-gated P2X receptor channel , 2017, Nature Communications.

[96]  Yang Yang,et al.  Intersubunit physical couplings fostered by the left flipper domain facilitate channel opening of P2X4 receptors , 2017, The Journal of Biological Chemistry.

[97]  Wenjuan Wu,et al.  Investigating the binding mechanism of novel 6-aminonicotinate-based antagonists with P2Y12 by 3D-QSAR, docking and molecular dynamics simulations , 2017, Journal of biomolecular structure & dynamics.

[98]  R. Schmid,et al.  Unique residues in the ATP gated human P2X7 receptor define a novel allosteric binding pocket for the selective antagonist AZ10606120 , 2017, Scientific Reports.

[99]  C. Müller,et al.  Molecular Recognition of Agonists and Antagonists by the Nucleotide-Activated G Protein-Coupled P2Y2 Receptor. , 2017, Journal of medicinal chemistry.

[100]  G. Schmalzing,et al.  Localization of the gate and selectivity filter of the full-length P2X7 receptor , 2017, Proceedings of the National Academy of Sciences.

[101]  P. Xiao,et al.  In silico Approach for Anti-Thrombosis Drug Discovery: P2Y1R Structure-Based TCMs Screening , 2017, Front. Pharmacol..

[102]  C. Müller,et al.  Development of Potent and Selective Antagonists for the UTP-Activated P2Y4 Receptor. , 2017, Journal of medicinal chemistry.

[103]  Hong Liu,et al.  Design, synthesis, and biological evaluation of 2-(phenoxyaryl)-3-urea derivatives as novel P2Y1 receptor antagonists. , 2018, European journal of medicinal chemistry.

[104]  Min Xu,et al.  The Fourth Industrial Revolution: Opportunities and Challenges , 2018 .

[105]  A. Brancale,et al.  The Molecular Determinants of Small-Molecule Ligand Binding at P2X Receptors , 2018, Front. Pharmacol..

[106]  Torsten Schwede,et al.  SWISS-MODEL: homology modelling of protein structures and complexes , 2018, Nucleic Acids Res..

[107]  R. Schmid,et al.  Mapping the Allosteric Action of Antagonists A740003 and A438079 Reveals a Role for the Left Flipper in Ligand Sensitivity at P2X7 Receptors , 2018, Molecular Pharmacology.

[108]  Yao-Yuan Liu,et al.  A review of bioinformatic methods for forensic DNA analyses. , 2018, Forensic science international. Genetics.

[109]  Xudong Huang,et al.  Deep learning and virtual drug screening , 2018, Future medicinal chemistry.

[110]  D. Major,et al.  A promising drug candidate for the treatment of glaucoma based on a P2Y6-receptor agonist , 2018, Purinergic Signalling.

[111]  M. Hattori,et al.  Druggable negative allosteric site of P2X3 receptors , 2018, Proceedings of the National Academy of Sciences.

[112]  Chen Cui,et al.  Computational chemical biology and drug design: Facilitating protein structure, function, and modulation studies , 2018, Medicinal research reviews.

[113]  Demis Hassabis,et al.  A general reinforcement learning algorithm that masters chess, shogi, and Go through self-play , 2018, Science.

[114]  Kathia Maria Honorio,et al.  Advances with support vector machines for novel drug discovery , 2018, Expert opinion on drug discovery.

[115]  J. Angulo,et al.  Mapping a novel positive allosteric modulator binding site in the central vestibule region of human P2X7 , 2019, Scientific Reports.

[116]  Volkan Atalay,et al.  Recent applications of deep learning and machine intelligence on in silico drug discovery: methods, tools and databases , 2018, Briefings Bioinform..